Patents by Inventor Kurt Scudder

Kurt Scudder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8058008
    Abstract: Cells are genetically modified to express a luminophore, e.g., a modified (F64L, S65T, Y66H) Green Fluorescent Protein (GFP, EGFP) coupled to a component of an intracellular signalling pathway such as a transcription factor, a cGMP- or cAMP-dependent protein kinase, a cyclin-, calmodulin- or phospholipid-dependent or mitogen-activated serine/threonin protein kinase, a tyrosine protein kinase, or a protein phosphatase (e.g. PKA, PKC, Erk, Smad, VASP, actin, p38, Jnk1, PKG, IkappaB, CDK2, Grk5, Zap70, p85, protein-tyrosine phosphatase 1C, Stat5, NFAT, NFkappaB, RhoA, PKB). An influence modulates the intracellular signalling pathway in such a way that the luminophore is being redistributed or translocated with the component in living cells in a manner experimentally determined to be correlated to the degree of the influence.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: November 15, 2011
    Assignee: Fisher Bioimage APS
    Inventors: Ole Thastrup, Sara Petersen Bjørn, Soren Tullin, Kasper Almholt, Kurt Scudder
  • Publication number: 20090023598
    Abstract: A method for screening a library of compounds to detect a biologically active compound that modulates intracellular translocation of a subunit of a component of an intracellular pathway affecting intracellular processes includes: culturing one or more cells containing a nucleotide sequence coding for a hybrid polypeptide comprising a luminophore linked to the subunit of the component; introducing a compound of the library of compounds into the cell culture; screening the compound to determine whether the compound modulates the intracellular translocation of the subunit of the component; measuring light emitted from the luminophore to determine a first distribution; measuring light emitted from the luminophore to determine a second distribution; computing a variation between the first distribution and the second distribution by processing the measured light, any variation is indicative that the compound is biologically active. The method is also performed with a library of compounds.
    Type: Application
    Filed: October 29, 2007
    Publication date: January 22, 2009
    Applicant: FISHER BIOIMAGE APS
    Inventors: Ole Thastrup, Sara Petersen Bjorn, Soren Tullin, Kasper Almholt, Kurt Scudder
  • Publication number: 20050112697
    Abstract: A method and apparatus for screening an array of test compounds for bioactivity by contacting an array of test compounds with a detector layer capable of detecting bioactivity, and detecting a detector layer response. The detector layer is comprised of physiologically viable cells. The method and apparatus allow a large number of test compounds to be simultaneously assayed in parallel without the need for complex fluidic devices.
    Type: Application
    Filed: December 3, 2003
    Publication date: May 26, 2005
    Inventors: Bernard Terry, Kurt Scudder, Per Olaf Arkhammer, Ole Thastrup
  • Publication number: 20030082564
    Abstract: Cells are genetically modified to expresss a luminophore, e.g., a modified (F64L, S65T, Y66H) Green Fluorescent Protein (GFP, EGFP) coupled to a component of an intracellular signalling pathway such as a transcription factor, a cGMP- or cAMP-dependent protein kinase, a cyclin-, calmodulin- or phospholipid-dependent or mitogen-activated serine/threonin protein kinase, a tyrosine protein kinase, or a protein phosphatase (e.g. PKA, PKC, Erk, Smad, VASP, actin, p38, Jnk1, PKG, IkappaB, CDK2, Grk5, Zap70, p85, protein-tyrosine phosphatase 1C, Stat5, NFAT, NFkappaB, RhoA, PKB). An influence modulates the intracellular signalling pathway in such a way that the luminophore is being redistributed or translocated with the component in living cells in a manner experimentally determined to be correlated to the degree of the influence.
    Type: Application
    Filed: February 5, 2002
    Publication date: May 1, 2003
    Applicant: BioImage A/S
    Inventors: Ole Thastrup, Sara Petersen Bjorn, Soren Tullin, Kasper Almholt, Kurt Scudder
  • Patent number: 6518021
    Abstract: Cells are genetically modified to express a luminophore, e.g., a modified (F64L, S65T, Y66H) Green Flourescent Protein (GFP, EGFP) coupled to a component of an intracellular signalling pathway such as a transcription factor, a cGMP- or cAMP-dependent protein kinase, a cyclin-, calmodulin- or phospholipid-dependent or mitogen-activated serine/threonin protein kinase, a tryosine protein kinase, or a protein phosphatase (e.g. PKA, PKC, Erk, Smad, VASP, actin, p38, Jnkl, PKG, IkappaB, CDK2, Grk5, Zap70, p85, protein-tyrosine phosphatase 1C, Stat5, NFAT, NFkappaB, RhoA, PKB). An influence modulates the intracellular signaling pathway in such a way that the luminophore is being redistributed or translocated with the component in living cells in a manner experimentally determined to be correlated to the degree of influence.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: February 11, 2003
    Assignee: BioImage A/S
    Inventors: Ole Thastrup, Sara Petersen Bjørn, Soren Tullin, Kasper Almholt, Kurt Scudder
  • Patent number: 5721135
    Abstract: The present invention relates to a rapid automated device for identifying biologically active substances by their effect on living cells which includes a flow chamber defined by a bottom wall with a plane optical surface through which the content of the chamber can be monitored and a ring shaped wall having an edge adjacent the plane optical surface leaving a gap between the edge and optical surface wherein the width of the gap allows liquid but not matrix to pass. The flow chamber also including an inlet through which fluids can be transported into the chamber and a device to control the distance between the edge and the optical surface wherein the matrix is momentarily allowed to pass.
    Type: Grant
    Filed: July 6, 1995
    Date of Patent: February 24, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Ole Thastrup, Kurt Scudder, Jaromir Ruzicka